2026-07-21T14:14:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/151372025-05-27T12:32:56Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Torres, Montserrat author Casado-Fernández, Guiomar author Vigon-Hernandez, Lorena author Rodríguez-Mora, Sara author Mateos, Elena author Ramos-Martín, Fernando author López-Wolf, Daniel author Sanz-Moreno, José author Ryan-Murua, Pablo author Taboada-Martínez, María Luisa author Lopez-Huertas, Maria Rosa author Cervero, Miguel author Coiras, Mayte author Multidisciplinary Group of Study of COVID-19 (MGS-COVID) author Cascajero Díaz, Almudena author García-Pérez, Javier author 2022-06 Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/ml (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D3) for 14 days, in comparison with 2000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/ml on average in 2000 IU/day versus 29 ng/ml in 10,000 IU/day group (p < 0.0001). Although levels of inflammatory cytokines were not modified by treatment with 10,000 IU/day, there was an increase of anti-inflammatory cytokine IL-10 and higher levels of CD4+ T cells, with predominance of T central memory subpopulation. Cytotoxic response against pseudotyped SARS-CoV-2 infected cells was increased more than 4-fold in patients who received 10,000 IU/day. Moreover, levels of IFNγ were significantly higher in this group. Beneficial effect of supplementation with 10,000 IU/day was also observed in participants who developed ARDS and stayed at the hospital for 8.0 days, whereas those who received 2000 IU/day stayed for 29.2 days (p = 0.0381). Administration of high doses of vitamin D3 as adjuvant of the standard care treatment during hospitalization for COVID-19 may improve the inflammatory environment and cytotoxic response against pseudotyped SARS-CoV-2 infected cells, shortening the hospital stay and, possibly, improving the prognosis. Biomed Pharmacother. 2022 Jun;150:112965. 10.1016/j.biopha.2022.112965 1950-6007 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 35468580 http://hdl.handle.net/20.500.12105/15137 COVID-19 SARS-CoV-2 Vitamin D supplementation Immune cytotoxic response Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D